BridgeMD
New treatment option for Cardiogenic Shock
Official title Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
ClinicalTrials.gov ID: NCT07345559
What this study is testing
- What it's testing
- Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged ≥18 years
- Cardiogenic shock state, according to the consensus definition,
- SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C
- Consent from the patient or close relative / trusted person or emergency inclusion procedure
- Benefiting fromciary of a social security scheme
You likely can't join if
- Catecholamine infusion for more than 24 consecutive hours;
- CVP \< 5 mm Hg at inclusion;
- MAP \> 70 mmHg at inclusion;
- Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to...
- Chronic dialysis or presence of renal replacement therapy criteria at inclusion ;
- Recovered cardiopulmonary arrest within 7 days prior to inclusion;
See the full eligibility criteria
- Aged ≥18 years
- Cardiogenic shock state, according to the consensus definition,
- SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C
- Consent from the patient or close relative / trusted person or emergency inclusion procedure
- Benefiting fromciary of a social security scheme
- Catecholamine infusion for more than 24 consecutive hours;
- CVP \< 5 mm Hg at inclusion;
- MAP \> 70 mmHg at inclusion;
- Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion;
- Chronic dialysis or presence of renal replacement therapy criteria at inclusion ;
- Recovered cardiopulmonary arrest within 7 days prior to inclusion;
- Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded);
- Primary diagnosis of tamponade, pulmonary embolism, or septic shock;
- Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations;
- Absence of central venous access;
- Known pregnancy or current breastfeeding;
- Under legal guardianship, curatorship, or judicial protection.
The study team makes the final eligibility decision.
Where it's taking place
- Amiens, France
- Créteil, France
- Massy, France
- Neuilly-sur-Seine, France
- Orléans, France
- Paris, France
- Saint-Cyr-sur-Loire, France
- Saint-Denis, France
- Strasbourg, France
- Toulouse, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amiens, France; Créteil, France; Massy, France; Neuilly-sur-Seine, France; Orléans, France; Paris, France and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.